Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of IMO 9200 in volunteers

Next Previous
Search
Trial Profile

Phase I trial of IMO 9200 in volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMO 9200 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Sponsors Aceragen; Idera Pharmaceuticals

    • Most Recent Events

    • 18 May 2015 Results published in the Idera Pharmaceuticals Media Release.
    • 18 May 2015 Status changed from recruiting to completed, according to an Idera Pharmaceuticals media release.
    • 07 Nov 2014 Idera Pharmaceuticals expects to select a lead autoimmune disease indication for further development of IMO-9200 in the first half of 2015, according to a media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top